BridgeBio Pharma (Nasdaq: BBIO) presented new analyses from its Phase 3 ATTRibute-CM study of Attruby (acoramidis) for transthyretin amyloid cardiomyopathy (ATTR-CM) at the European Society of Cardiology Congress 2026, according to a company statement.

Data from a cardiac magnetic resonance imaging (CMR) substudy showed that 54% of acoramidis-treated patients demonstrated clinically meaningful improvement in left ventricular systolic function at Month 30, compared with 20% of placebo-treated patients. At Month 42, 53% of patients on continuous acoramidis maintained that level of improvement. In a more conservative analysis, improvement was observed in 34% of acoramidis-treated patients versus 9% of placebo-treated patients at Month 30.

A post-hoc analysis measured days lost to death and cardiovascular-related hospitalization. Patients receiving acoramidis had an estimated 7.5% of days lost versus 11.7% with placebo through Month 30. Over 36 months, acoramidis-treated patients had an observed 65 additional days alive and out of the hospital compared with baseline placebo patients.

Data from the open-label extension through Month 54 showed all-cause mortality of 30.4% with continuous acoramidis versus 66.7% with placebo-to-acoramidis in the p.Val142Ile genetic variant subgroup. Across the overall variant ATTR-CM population, all-cause mortality was 24.3% with continuous acoramidis versus 57.9% with placebo-to-acoramidis. No new safety signals were observed through Month 54.

The p.Val142Ile variant carries a frequency of 3–4% in the U.S. Black population and is described as disproportionately affecting individuals of Western African ancestry.

BridgeBio also reported it has dosed the first participant in ASCEND-ATTR, a Phase 3b/4 study examining whether acoramidis produces sustained improvement in myocardial structural disease progression and amyloid burden.

Acoramidis is approved in the U.S. as Attruby and in Europe as BEYONTTRA, among other regulatory approvals. The findings were simultaneously published in the European Journal of Heart Failure.